TaperCommunityTaperCommunity
Forums/Drug Profiles/

Clomipramine Tapering Guide

clomipramine

TCAFDA 1989
Go to Community Forum

Boxed Warning

Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.

Overview

Clomipramine is a tricyclic antidepressant with the strongest serotonin reuptake inhibition of all TCAs. It is the only TCA FDA-approved for obsessive-compulsive disorder (OCD) and is considered a gold-standard treatment for severe OCD.

Common Doses

25mg, 50mg, 75mg, 100mg

Formulations

Capsules: 25mg, 50mg, 75mg

Pregnancy

Category C (risk cannot be ruled out)

Mechanism of Action

Potent inhibitor of serotonin reuptake (most serotonergic TCA) and moderate inhibitor of norepinephrine reuptake. Its metabolite desmethylclomipramine is a potent norepinephrine reuptake inhibitor. Also has anticholinergic, antihistaminic, and alpha-adrenergic blocking activity.

Taper Notes

Strong serotonergic TCA. Withdrawal can be severe. Capsules can be opened for bead counting.

Hyperbolic Tapering Guidance

Due to strong serotonin reuptake inhibition, withdrawal can resemble SSRI discontinuation. Slow hyperbolic taper recommended.

Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.

Common Withdrawal Symptoms

brain zapsnauseainsomniaanxietydizzinesselectric shocks

Interactions & Safety

Drug Interactions

  • MAOIs — contraindicated (serotonin syndrome and hypertensive crisis)
  • CYP2D6 inhibitors significantly increase clomipramine levels
  • CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) increase levels — fluvoxamine can cause dramatic elevations

Food Interactions

  • Food does not significantly affect absorption
  • Grapefruit juice may increase levels
  • Avoid alcohol (additive CNS depression)

Contraindications

  • MAOIs within 14 days
  • Acute recovery period post-myocardial infarction
  • Known hypersensitivity to clomipramine or other TCAs

Toxicity

Cardiotoxic in overdose (QRS widening, arrhythmias). Seizures (dose-dependent, especially >250mg/day). Serotonin syndrome risk. Anticholinergic toxicity.

Pharmacokinetics

ADME Profile

Absorption

Well absorbed after oral administration. Extensive first-pass metabolism; bioavailability ~50%. Tmax 2–6 hours. Food does not significantly affect absorption.

Distribution

~17 L/kg

Metabolism

Hepatic via CYP2D6, CYP1A2, CYP2C19, and CYP3A4 to the active metabolite desmethylclomipramine and hydroxylated metabolites.

Elimination

Renal (~51–60% as metabolites) and fecal (~24–32%). Less than 1% excreted unchanged in urine.

Protein Binding

~97–98%

Clearance

Apparent oral clearance variable; auto-inhibition of CYP2D6 with chronic dosing.

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber

Other Drug Profiles

Sources & References

Clomipramine (clomipramine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.

Encyclopedic & chemical databases

Neutral, high-authority entity references.

Deprescribing-specific resources

Clinician-facing references on tapering protocols.

Patient-advocacy & lived-experience

Long-running communities documenting withdrawal experience.

TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.